David S. Hong, MD, University of Texas MD Anderson Cancer Center (IMAGE)

University of Texas M. D. Anderson Cancer Center

David S. Hong, MD, University of Texas MD Anderson Cancer Center

Caption

For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study.

Credit

The University of Texas MD Anderson Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.